SNY Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

11.18B

+5.79%

0.807

+18.26%

10.16B

+2.63%

0.989

-3.22%

10.72B

+7.26%

0.000

-100%

Estimates Revision

The market is revising Upward the revenue expectations for Sanofi (SNY) for FY2025, with the revenue forecasts being adjusted by 0.54% over the past three months. During the same period, the stock price has changed by -1.41%.

Revenue Estimates for FY2025

Revise Upward

+0.54%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-49.67%

In Past 3 Month

Stock Price

Go Down

-1.41%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 63.50 USD with a low forecast of 58.00 USD and a high forecast of 69.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

58.00

Averages

63.50

High

69.00

Current: 0.000

Low

58.00

Averages

63.50

High

69.00

Barclays

Overweight -> Equal Weight

downgrade

2026-01-06

New

Reason

Barclays

Price Target

2026-01-06

New

downgrade

Overweight -> Equal Weight

Reason

Barclays downgraded Sanofi to Equal Weight from Overweight.

HSBC

Rajesh Kumar

Buy

downgrade

2025-12-10

Reason

HSBC

Rajesh Kumar

Price Target

2025-12-10

downgrade

Buy

Reason

HSBC analyst Rajesh Kumar lowered the firm's price target on Sanofi to EUR 100 from EUR 102 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."

Guggenheim

Seamus Fernandez

Buy -> Neutral

downgrade

2025-12-09

Reason

Guggenheim

Seamus Fernandez

Price Target

2025-12-09

downgrade

Buy -> Neutral

Reason

Guggenheim analyst Seamus Fernandez downgraded Sanofi to Neutral from Buy.

Guggenheim

Seamus Fernandez

Buy -> Neutral

downgrade

2025-12-09

Reason

Guggenheim

Seamus Fernandez

Price Target

2025-12-09

downgrade

Buy -> Neutral

Reason

As previously reported, Guggenheim analyst Seamus Fernandez downgraded Sanofi to Neutral from Buy and removed the firm's previous price target on the shares. The firm had hoped to see materially improved pipeline-driven upside, but this "failed to materialize" and it now sees no thesis changing pipeline catalysts for at least the next 12 months, the analyst tells investors.

Oppenheimer

Trevor Allred

Outperform

maintain

$60 -> $62

2025-11-06

Reason

Oppenheimer

Trevor Allred

Price Target

$60 -> $62

2025-11-06

maintain

Outperform

Reason

Oppenheimer analyst Trevor Allred raised the firm's price target on Dianthus (DNTH) to $62 from $60 and keeps an Outperform rating on the shares. The firm notes Dianthus reported a Q3 net loss of $37M, in line with its $36M estimate. Oppenheimer's focus is narrowing onto CIDP, as claseprubart's Phase 3 enrollment looks to be garnering subjects from Sanofi's (SNY) riliprubart and other therapeutic options. The firm expects CIDP results to garner more investor attention.

Jefferies

Buy

initiated

€100

2025-10-27

Reason

Jefferies

Price Target

€100

2025-10-27

initiated

Buy

Reason

Jefferies assumed coverage of Sanofi with a Buy rating and EUR 100 price target, calling it the analyst's EU Pharma top pick. Valued at about a 15% discount to the sector, the firm believes the perception that Sanofi lacks a pipeline to offset the 2031 Dupixent patent expiry is "incorrect," with upcoming catalysts over the next 12 months set to build confidence, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Sanofi SA (SNY.O) is 0.00, compared to its 5-year average forward P/E of 10.14. For a more detailed relative valuation and DCF analysis to assess Sanofi SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

10.14

Current PE

0.00

Overvalued PE

13.93

Undervalued PE

6.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

9.08

Current EV/EBITDA

8.03

Overvalued EV/EBITDA

9.79

Undervalued EV/EBITDA

8.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.57

Current PS

2.18

Overvalued PS

2.80

Undervalued PS

2.34

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 231.75% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SNY News & Events

Events Timeline

No data

News

6.0

01-07Benzinga

BofA Upgrades Regeneron to Buy, Raises Price Target to $860

9.0

01-06Benzinga

Sanofi's Tolebrutinib Application Rejected by FDA Due to Liver Injury Risks

9.0

01-05NASDAQ.COM

Sanofi Seeks FDA Approval for Tzield to Treat Children Aged 1 and Up

People Also Watch

Frequently Asked Questions

What is Sanofi SA (SNY) stock price today?

The current price of SNY is 48.13 USD — it has decreased -0.5 % in the last trading day.

What is Sanofi SA (SNY)'s business?

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

What is the price predicton of SNY Stock?

What is Sanofi SA (SNY)'s revenue for the last quarter?

Sanofi SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Sanofi SA (SNY)'s earnings per share (EPS) for the last quarter?

Sanofi SA. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Sanofi SA (SNY)'s fundamentals?

How many employees does Sanofi SA (SNY). have?

Sanofi SA (SNY) has 84587 emplpoyees as of January 09 2026.

What is Sanofi SA (SNY) market cap?

Today SNY has the market capitalization of 116.61B USD.